Autologous ADRC therapy for partial-thickness rotator cuff tears
phase 2drug program · high · Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat symptomatic chronic partial-thickness rotator cuff tears and improve shoulder function compared with corticosteroid injection.
Single ultrasound-guided injection of autologous adipose-derived regenerative cells into the partial-thickness rotator cuff tear, compared with corticosteroid control; includes pilot, larger randomized study, and long-term follow-up.
RC-004 longitudinal follow-up study was opened to follow subjects from the RC-002 study for 3 years.
Pilot and long-term follow-up publications reported no severe adverse events related to UA-ADRC injection and higher ASES shoulder scores versus corticosteroid control at reported follow-up timepoints.
Autologous adipose-derived regenerative cell platform
undisclosedplatform · high · Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Prepare a patient's own adipose-derived regenerative cells for therapeutic regenerative-medicine applications, with emphasis on orthopedics and tissue repair.
Point-of-care isolation of fresh, uncultured, unmodified autologous adipose-derived regenerative cells from lipoaspirate using the Transpose process.
Company pipeline and publications describe the platform as the basis for multiple clinical and research applications.
Publications describe UA-ADRCs as autologous orthobiologics with potential advantages over non-enzymatically isolated cells, bone marrow aspirate concentrate, and cultured cells.
Autologous ADRC therapy for facet joint osteoarthritis and chronic lumbar back pain
undiscloseddrug program · high · Fri Dec 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and efficacy of ADRC injection for chronic lumbar back pain due to facet joint osteoarthritis.
Prospective, randomized, active-controlled, single-site study comparing a single Transpose RT-generated ADRC injection into the facet joint against control treatment.
Clinical trial record published for safety and efficacy evaluation.
Autologous ADRC therapy for wrist osteoarthritis
undiscloseddrug program · high · Wed Nov 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether adult adipose-derived regenerative cells can treat chronic wrist osteoarthritis.
Prospective, randomized, double-blinded, active-controlled, single-site safety and efficacy study using a single Transpose RT-generated ADRC injection into the wrist.
Clinical trial record published for wrist osteoarthritis study.
Autologous cell therapy for chronic venous stasis wounds
undiscloseddrug program · high · Thu Jun 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Promote healing of chronic venous stasis ulcers using autologous cell therapy.
Prospective, randomized, single-site safety and efficacy study using stromal vascular fraction injected around the wound rim after standard wound debridement, with treated collagen dressing, compared with standard care control.
Clinical trial record published for chronic venous stasis wound study.
Autologous ADRC therapy for chronic ischemic heart failure
undiscloseddrug program · medium
Develop regenerative cell therapy for chronic ischemic heart failure.
Autologous adipose-derived regenerative cell therapy listed in the company pipeline.
Listed on company pipeline.
Autologous ADRC therapy for knee osteoarthritis
undiscloseddrug program · medium
Develop regenerative cell therapy for knee osteoarthritis.
Autologous adipose-derived regenerative cell therapy listed in the company pipeline.
Listed on company pipeline.
UA-ADRC-assisted guided bone regeneration
exploratoryresearch program · medium
Improve guided bone regeneration for oral surgery applications before implant placement, including maxillary sinus augmentation and lateral alveolar ridge augmentation.
Combined application of unmodified, fresh autologous adipose-derived regenerative cells and plasma rich in growth factors.
First-in-human case report and literature review published.
Publication describes improved guided bone regeneration using UA-ADRCs plus plasma rich in growth factors in a first-in-human case report.
